Retrophin (NASDAQ:RTRX) Stock Rating Upgraded by BidaskClub

Retrophin (NASDAQ:RTRX) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday, BidAskClub reports.

Several other brokerages also recently commented on RTRX. Canaccord Genuity reissued a “speculative buy” rating and issued a GBX 70 ($0.91) price objective on shares of Bacanora Lithium in a research note on Monday, July 1st. William Blair reaffirmed a “buy” rating on shares of Retrophin in a research report on Friday, July 5th. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Finally, Barclays assumed coverage on GENFIT S A/ADR in a research report on Monday, April 22nd. They set an “overweight” rating and a $55.00 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $44.50.

Shares of Retrophin stock opened at $21.55 on Thursday. The stock has a market capitalization of $892.97 million, a P/E ratio of -8.48 and a beta of 0.93. Retrophin has a 52 week low of $17.53 and a 52 week high of $33.00. The business has a 50 day moving average of $19.64. The company has a current ratio of 4.57, a quick ratio of 4.52 and a debt-to-equity ratio of 0.69.

Retrophin (NASDAQ:RTRX) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.41). The company had revenue of $39.57 million during the quarter, compared to analysts’ expectations of $41.40 million. Retrophin had a negative return on equity of 41.38% and a negative net margin of 75.75%. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the company earned ($0.14) earnings per share. Equities analysts expect that Retrophin will post -3.02 EPS for the current fiscal year.

In related news, CFO Laura Clague sold 2,500 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $18.25, for a total transaction of $45,625.00. Following the completion of the sale, the chief financial officer now directly owns 14,750 shares of the company’s stock, valued at $269,187.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William E. Rote sold 1,625 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $17.77, for a total value of $28,876.25. The disclosure for this sale can be found here. Insiders have sold 10,819 shares of company stock valued at $194,503 over the last ninety days. 4.32% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. Handelsbanken Fonder AB lifted its position in Retrophin by 32.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 612,856 shares of the biopharmaceutical company’s stock valued at $12,312,000 after acquiring an additional 150,000 shares in the last quarter. Sphera Funds Management LTD. lifted its position in Retrophin by 33.8% in the 1st quarter. Sphera Funds Management LTD. now owns 435,678 shares of the biopharmaceutical company’s stock valued at $9,859,000 after acquiring an additional 110,000 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Retrophin by 3.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,944,288 shares of the biopharmaceutical company’s stock valued at $43,999,000 after acquiring an additional 73,284 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Retrophin in the 1st quarter valued at approximately $217,000. Finally, DekaBank Deutsche Girozentrale lifted its position in Retrophin by 22.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,400 shares of the biopharmaceutical company’s stock valued at $575,000 after acquiring an additional 3,600 shares in the last quarter.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Read More: Resistance Level

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.